Development of DNA Vaccine Candidate against SARS-CoV-2

Wang, Xinyun; Rcheulishvili, Nino; Cai, Jie; Liu, Cong; Xie, Fengfei; Hu, Xiaoyi; Yang, Nuo; Hou, Mengqi; Papukashvili, Dimitri; He, Yaohua; Wang, Peng George

doi:10.3390/v14051049

Cited by 8 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Similar approach with injection and electroporation was used by the other studies on DNA vaccines. 8,10,12 In addition, the authorized DNA vaccine ZyCoV-D is intradermally immunized via a needle-free injection system with a Pharmajet Tropis device, which generates a stream of pressurized fluid penetrating the skin at high velocity contributing to uniform dispersion and efficient uptake of DNA molecules. 16,51 DNA vaccines could be designed and generated rapidly, applicable to mass production at low cost and induce robust immune responses without anti-vector responses.…”

Section: Discussionmentioning

confidence: 99%

“…A controlled electric field is generated at the injection site to enhance the cellular uptake of the DNA plasmid 15 . Similar approach with injection and electroporation was used by the other studies on DNA vaccines 8,10,12 . In addition, the authorized DNA vaccine ZyCoV‐D is intradermally immunized via a needle‐free injection system with a Pharmajet Tropis device, which generates a stream of pressurized fluid penetrating the skin at high velocity contributing to uniform dispersion and efficient uptake of DNA molecules 16,51 …”

Section: Discussionmentioning

confidence: 99%

“…6,7 One DNA vaccine candidate contained ectodomain of S-protein (1-1213) with a trimeric foldon tag at the C-terminus and 6P mutations (F817P, A892P, A899P, A942P, K986P, V987P) induced neutralizing antibody (NAb) responses in mice. 8 ZyCoV-D, INO-4800, and pSARS2-S, carrying the SARS-CoV-2 spike gene, induced protective immune responses in animals. [9][10][11] COVID-eVax, encoding secreted monomeric SARS-CoV-2 RBD, induced stronger antibody responses than DNA vaccine candidates encoding full-length S protein and S1 subunit protein.…”

Section: Introductionmentioning

confidence: 98%

“…Due to the advantages of high immunogenicity, simple production, stability, and no anti‐vector responses, several DNA vaccine candidates against COVID‐19 have been developed and studied 6,7 . One DNA vaccine candidate contained ectodomain of S‐protein (1‐1213) with a trimeric foldon tag at the C‐terminus and 6P mutations (F817P, A892P, A899P, A942P, K986P, V987P) induced neutralizing antibody (NAb) responses in mice 8 . ZyCoV‐D, INO‐4800, and pSARS2‐S, carrying the SARS‐CoV‐2 spike gene, induced protective immune responses in animals 9–11 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

Zhao²,

Duan

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic posed great impacts on public health. To fight against the pandemic, robust immune responses induced by vaccination are indispensable. Previously, we developed a subunit vaccine adjuvanted by aluminum hydroxide, ZF2001, based on the dimeric tandem-repeat RBD immunogen, which has been approved for clinical use. This dimeric RBD design was also explored as an mRNA vaccine. Both showed potent immunogenicity. In this study, a DNA vaccine candidate encoding RBD-dimer was designed. The humoral and cellular immune responses induced by homologous and heterologous primeboost approaches with DNA-RBD-dimer and ZF2001 were assessed in mice.Protection efficacy was studied by the SARS-CoV-2 challenge. We found that the DNA-RBD-dimer vaccine was robustly immunogenic. Priming with DNA-RBD-dimer followed by ZF2001 boosting induced higher levels of neutralizing antibodies than homologous vaccination with either DNA-RBD-dimer or ZF2001, elicited polyfunctional cellular immunity with a T H 1-biased polarization, and efficiently protected mice against SARS-CoV-2 infection in the lung. This study demonstrated the robust and protective immune responses induced by the DNA-RBD-dimer candidate and provided a heterologous prime-boost approach with DNA-RBD-dimer and ZF2001.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

Zhao²,

Duan

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Nucleic acid vaccines, particularly mRNA vaccines have elicited high efficiency against ongoing coronavirus disease 2019 (COVID-19) pandemic ( 26 – 31 ). Moreover, DNA vaccines also show great results ( 32 – 36 ), e.g., India has approved a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ( 37 ). Nucleic acid vaccines have a number of advantages compared with traditional vaccines.…”

Section: Introductionmentioning

confidence: 99%

Strategy of developing nucleic acid-based universal monkeypox vaccine candidates

Papukashvili

Rcheulishvili²,

Liu³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Until May 2022, zoonotic infectious disease monkeypox (MPX) caused by the monkeypox virus (MPXV) was one of the forgotten viruses considered to be geographically limited in African countries even though few cases outside of Africa were identified. Central and West African countries are known to be endemic for MPXV. However, since the number of human MPX cases has rapidly increased outside of Africa the global interest in this virus has markedly grown. The majority of infected people with MPXV have never been vaccinated against smallpox virus. Noteworthily, the MPXV spreads fast in men who have sex with men (MSM). Preventive measures against MPXV are essential to be taken, indeed, vaccination is the key. Due to the antigenic similarities, the smallpox vaccine is efficient against MPXV. Nevertheless, there is no specific MPXV vaccine until now. Nucleic acid vaccines deserve special attention since the emergency approval of two messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines in 2020. This milestone in vaccinology has opened a new platform for developing more mRNA- or DNA-based vaccines. Certainly, this type of vaccine has a number of advantages including time- and cost-effectiveness over conventional vaccines. The platform of nucleic acid-based vaccines gives humankind a huge opportunity. Ultimately, there is a strong need for developing a universal vaccine against MPXV. This review will shed the light on the strategies for developing nucleic acid vaccines against MPXV in a timely manner. Consequently, developing nucleic acid-based vaccines may alleviate the global threat against MPXV.

show abstract

Immunogenicity of novel DNA vaccines encoding receptor‐binding domain (RBD) dimer‐Fc fusing antigens derived from different SARS‐CoV‐2 variants of concern

Zhang

Wang

Yang

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The continuously emerging of severe acute respiratory syndrome coronavirus‐2 variants of concern (VOCs) led to a decline in effectiveness of the first‐generation vaccines. Therefore, optimized vaccines and vaccination strategies, which show advantages in protecting against VOCs, are urgently needed. Here we constructed an optimized DNA vaccine plasmid containing built‐in CpG adjuvant, and designed vaccine candidates encoding five forms of antigens derived from Wuhan‐Hu‐1. The results showed that plasmid with receptor binding domain (RBD) dimer‐Fc fusing antigen (2RBD‐Fc) induced the highest level of RBD‐specific IgG and neutralizing antibodies in mice. Then 2dRBD‐Fc and 2omRBD‐Fc vaccines, respectively derived from delta and omicron VOCs, were constructed. The 2dRBD‐Fc induced potent humoral and cellular immune responses, while the immunogenicity of 2omRBD‐Fc was low. We also observed that sequential immunization with 2RBD‐Fc, 2dRBD‐Fc and 2omRBD‐Fc effectively elicited neutralizing antibodies against each immunized strain, and RBD‐specific T cell responses. To be noted, the Wuhan‐Hu‐1, delta and omicron neutralizing antibody titers induced by sequential immunization were comparable to that induced by repetitive immunization with 2RBD‐Fc, 2dRBD‐Fc or 2omRBD‐Fc respectively. The results suggest that sequential immunization with DNA vaccines encoding potent antigens derived from different VOCs, may be a promising strategy to elicit immune responses against multiple variants.

show abstract

Development of DNA Vaccine Candidate against SARS-CoV-2

Cited by 8 publications

References 59 publications

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

Strategy of developing nucleic acid-based universal monkeypox vaccine candidates

Immunogenicity of novel DNA vaccines encoding receptor‐binding domain (RBD) dimer‐Fc fusing antigens derived from different SARS‐CoV‐2 variants of concern

Contact Info

Product

Resources

About